Skip to main content
. Author manuscript; available in PMC: 2020 Jan 3.
Published in final edited form as: N Engl J Med. 2018 Nov 10;380(1):23–32. doi: 10.1056/NEJMoa1811403

Table 1.

Baseline Characteristics of the 25,871 VITAL Participants, According to Randomized Assignment to Marine Omega-3 Fatty Acids.a

Baseline
Characteristic
All Participants Treatment Group
Omega-3s Placebo
N 25,871 12,933 12,938
Sex, % female 13085 (50.6) 6547 (50.6) 6538 (50.5)
Mean age ± SD, years 67.1 ± 7.1 67.2 ± 7.1 67.1 ± 7.1
Race/ethnicity, %
 Non-Hispanic White 18046 (71.3) 9044 (71.5) 9002 (71.2)
 African American 5106 (20.2) 2549 (20.1) 2557 (20.2)
 Hispanic (not African American) 1013 (4.0) 491 (3.9) 522 (4.1)
 Asian/Pacific Islander 388 (1.5) 200 (1.6) 188 (1.5)
 American Indian/Alaskan Native 228 (0.9) 120 (0.9) 108 (0.9)
 Other/unknown 523 (2.1) 249 (2.0) 274 (2.2)
Mean body mass index ± SD, kg/m2 28.1 (5.7) 28.1 ± 5.7 28.1 ± 5.8
Current smoking, % 1836 ( 7.2) 920 ( 7.2) 916 ( 7.2)
Hypertension, treated with medication, %, 12791 (49.8) 6338 (49.3) 6453 (50.2)
Cholesterol-lowering medication (current use), % 9524 (37.5) 4788 (37.7) 4736 (37.2)
Diabetes, % 3549 (13.7) 1799 (13.9) 1750 (13.5)
a

Abbreviations: SD = standard deviation. There were no significant differences in the baseline characteristics between the groups.